So EXEL has a time frame to determine if they want to invest cash in marketing (and sometimes in development, there may be other costs or a price for EXEL to pay to exercise this option) or just take the royalty and forget about it.Let's hope they conserve cash for Cabo!They are running numerous trials that will be serious cash drains........they need to be careful with multiple skillets.....its what killed their prospects before.......so many options all with serious money drain.Hope they just take the royalty. Doubt melanoma market would be in same league with Cabo.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra